Volume 85 Issue 34 | pp. 32-33
Issue Date: August 20, 2007

Pharma's Mixed Bag

Setbacks for blockbuster drugs sideswipe several drug firms' second-quarter results
Department: Business | Collection: Economy

AS ILLUSTRATED BY A WIDE RANGE of second-quarter results, the pharmaceutical industry's reliance on "blockbuster" drugs is a double-edged sword. Although Pfizer and GlaxoSmithKline were taken down a notch by pressures on multi-billion-dollar drugs, Merck and Schering-Plough are at their healthiest in years thanks to skyrocketing sales . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society